In the study of FLAURA and AURA3, Osimertinib showed more effective CNS efficacy and a reduced risk of CNS progression versus standard EGFR-TKIs in patients with untreated EGFR-mutated NSCLC [28,29]. Here, EGFR is linked to non-small cell lung carcinoma.